sitagliptin + Comparator: glimepiride + open-label metformin
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Type 2 Diabetes Mellitus, Non Insulin Dependent
Conditions
Type 2 Diabetes Mellitus, Non Insulin Dependent, Diabetes Mellitus, Non-Insulin-Dependent
Trial Timeline
May 1, 2008 → Oct 1, 2009
NCT ID
NCT00701090About sitagliptin + Comparator: glimepiride + open-label metformin
sitagliptin + Comparator: glimepiride + open-label metformin is a phase 3 stage product being developed by Merck for Type 2 Diabetes Mellitus, Non Insulin Dependent. The current trial status is completed. This product is registered under clinical trial identifier NCT00701090. Target conditions include Type 2 Diabetes Mellitus, Non Insulin Dependent, Diabetes Mellitus, Non-Insulin-Dependent.
What happened to similar drugs?
20 of 20 similar drugs in Type 2 Diabetes Mellitus, Non Insulin Dependent were approved
Approved (20) Terminated (0) Active (0)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00701090 | Phase 3 | Completed |
Competing Products
20 competing products in Type 2 Diabetes Mellitus, Non Insulin Dependent